Pharmaceuticals
Harbour BioMed Reports Full Year 2021 Financial Results: Empower Value Creation with Global Innovation Capabilities
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, March 24, 2022 /PRNewswire/ --Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on oncology a...
2022-03-25 10:22
3766
New clinical trial collaboration for Cu-64 SAR-bisPSMA in prostate cancer
SYDNEY, March 24, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that an investigator-initiated trial (IIT) will commence shortly...
2022-03-24 21:08
2538
Insilico Medicine Announces Strategic Collaboration with EQRx to Jointly Advance AI-driven Drug Discovery, Development and Commercialization for Multiple Targets
The collaboration leverages Insilico's end-to-end AI-driven Pharma.AI platform to discover novel small molecule drug candidates for multiple targets, along with EQRx's innovative business model to accelerate drug development and patient access to novel medicines at affordable prices NEW YORK, Ma...
2022-03-24 21:00
4551
Huma and AstraZeneca Partner to Accelerate Innovation for Digital-First Patient Care
Huma acquires AstraZeneca's digital health platform AMAZE™ and AstraZeneca
becomes a shareholder of Huma
LONDON and NEW YORK, March 23, 2022 /PRNewswire/ -- Huma Therapeutics Limited
2022-03-24 07:00
3948
Fosun International Announces 2021 Annual Results: Total Revenue Increased by 18% to RMB161.29 Billion, Striving to Pursue Steady and Sustainable Development
2021 Annual Results Summary and Highlights: * Total operating revenue for the year amounted to RMB161.29 billion, representing a year-on-year increase of 18%; profit attributable to owners of the parent reachedRMB10.09 billion, representing a year-on-year increase of 26%; * Profit of industria...
2022-03-23 23:01
4811
Telix Advances Development of Glioblastoma Therapy Program
MELBOURNE, Australia, March 23, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces it has made significant progress in advancing the Company's glioblastoma multiforme (GBM) therapy candidate TLX101 into the next stage of clinical development. TLX101 (4-L-...
2022-03-23 10:16
2705
Novavax and Serum Institute of India Announce First Emergency Use Authorization of Novavax' COVID-19 Vaccine in Adolescents ≥12 to <18 in India
* First authorization of Novavax' COVID-19 vaccine in adolescent population received * Covovax™ (SARS-CoV-2 rS Protein (COVID-19) recombinant spike protein Nanoparticle Vaccine) is the first protein-based COVID-19 vaccine authorizedfor adolescents ≥12 to <18 inIndia * Authorization highligh...
2022-03-23 09:31
4333
InnoCare Releases 2021 Annual Results and Business Highlights
BEIJING, March 22, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced 2021 annual results as of31 December 2021. Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare, said, "We are delighted ...
2022-03-23 08:08
3865
Brii Biosciences Provides Corporate Update and Reports Full Year 2021 Financial Results
– Advancing key programs in HBV, CNS, and HIV – – Received first BLA approval for COVID-19 Treatment in China and added to China's latest COVID-19 Diagnosis and Treatment Guidelines– – Multiple clinical value drivers expected across the portfolio in 2022 and beyond – – Cash, bank balances, an...
2022-03-23 07:20
5797
Fosun Pharma 2021 Annual Results Announcement: Accelerating the Globalization Comprehensively
The Proportion of Revenue from Innovative Products Continues to Increase Highlights: * Revenue for the year ended December 31, 2021 was RMB39,005 million, representing an increase of 28.70% YOY; * The proportion of revenue from new products as well as regions outside Mainland China and count...
2022-03-23 06:53
4004
WuXi Biologics Achieved Record Growth and Profitability in 2021
Banner Year for Commercial Manufacturing Revenue Increased by 83.3% Y-o-Y to RMB10,290.1 Million Gross Profit Increased by 90.6% Y-o-Y to RMB4,828.9 Million Net Profit Grew by 107.3% Y-o-Y to RMB3,508.6 Million Adjusted Net Profit Rose by 100.3% to RMB3,435.9 Million Total Backlog Grew 20.1% to ...
2022-03-23 00:38
3725
Jacobio Announces Annual Results of 2021, R&D Investment Increases 83%
BEIJING and SHANGHAI and BOSTON, March 22, 2022 /PRNewswire/ -- Jacobio Announced its 2021 annual results on 22 March. As a clinical-stage biotech company, Jacobio's revenue wasRMB152 million, which was generated from an out-licensing deal. Its R&D investment wasRMB421 million, showing an increas...
2022-03-22 22:50
2900
NIBIOHN Identifies Tissue-specific Exosome Marker Candidates from Blood
OSAKA, Japan, March 22, 2022 /PRNewswire/ -- The National Institutes of Biomedical Innovation, Health and Nutrition (hereinafter NIBIOHN) based in Ibaraki-shi, Osaka Prefecture, has successfully catalogued more than 4,000 proteins contained in exosomes in healthy human blood (serum and plasma). Us...
2022-03-22 14:00
1753
Ascentage Pharma's MDM2-p53 Inhibitor Alrizomadlin (APG-115) Granted Rare Pediatric Disease Designation by the US FDA for the Treatment of Neuroblastoma
SUZHOU, China, and ROCKVILLE, MD, March 21, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its novel MDM2-p53 inhibitor, alrizomadlin ...
2022-03-22 09:15
2428
Transcenta Announces Global Clinical Collaboration with Bristol Myers Squibb to Evaluate TST001 in Combination with Opdivo® in Patients with Locally Advanced or Metastatic Gastric / Gastroesophageal Junction Cancer
SUZHOU, China, March 22, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it has establis...
2022-03-22 08:19
3165
Cali Biosciences Announces Successful Results in Phase IIb Study of Long-Acting Ropivacaine (CPL-01) for Non-Opioid Treatment of Post-Operative Pain
SAN DIEGO, March 21, 2022 /PRNewswire/ -- Cali Biosciences Co., Ltd. (hereinafter referred to as "Cali Biosciences"), a biopharmaceutical company focused on the research and development of innovative drugs, announced successful results in its Phase IIb study of its perioperative long-acting anal...
2022-03-22 00:00
2231
Ascentage Pharma Announces 2021 Annual Results with Commercialization Programs Going Full Steam Ahead
SUZHOU, China and ROCKVILLE, Md., March. 21, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today released its annual results for full year 2021, during whi...
2022-03-21 23:11
3448
ABclonal Technology Joins YCharOS Industry Advisory Committee to Tackle Reproducibility Crisis in Biomedical Research
BOSTON, March 21, 2022 /PRNewswire/ -- ABclonal Technology, a rapidly growing life science research and diagnostic reagents manufacturer, today announced it has joined the Industry Advisory Committee (IAC) at YCharOS Inc., an open science company with the mission of characterizing commercially av...
2022-03-21 20:15
2254
RNAGENE Signs a Collaborative Research Agreement with PharmAbcine to Develop Novel mRNA Therapeutics
SEOUL, South Korea, March 21, 2022 /PRNewswire/ -- RNAGene Inc., a South Korean biotech which specializes in the development of mRNA (messenger ribonucleic acid)-based therapeutics, announced today that it has signed a Collaborative Research Agreement with PharmAbcine Inc. (KOSDAQ: 208340ks), a c...
2022-03-21 20:00
2562
Nuance Pharma Announces License and Supply Agreement with Bavarian Nordic on the Development and Commercialization of Respiratory Syncytial Virus (RSV) Vaccine for Adults in China and Selected Asian Markets
* Bavarian Nordic to receive up to USD 225 million in upfront and milestone payments in addition to tiered, double-digit royalties * Nuance Pharma obtains rights to commercialize MVA-BN® RSV in Chinese Mainland,Hong Kong, Macau, Taiwan, South Korea and Southeast Asia and will be responsible f...
2022-03-21 16:20
2094
Week's Top Stories
Most Reposted
Franchising & Licensing Asia 2026 Opens New Chapter Under MP, Strengthening Singapore's Position as Asia's Franchise and Licensing Hub
[Picked up by 309 media titles]
2026-07-30 10:45
J.P. Morgan Private Bank Earns Record 10 Accolades at The Asset Triple A Private Capital Awards 2026
[Picked up by 294 media titles]
2026-07-30 15:00KC Global Media announces new travel series "AXN Ultimate Challenge: Sarawak"
[Picked up by 291 media titles]
2026-07-30 09:12
ADA acquires Algonomy, strengthening its intelligent growth platform for a fully agentic experience
[Picked up by 290 media titles]
2026-07-30 15:30
Articura Launches a New Chapter for Sovereign Healthcare AI in Indonesia
[Picked up by 290 media titles]
2026-07-27 19:02
Most Read
Visa and Lianlian Advance Trusted B2B Agentic Commerce Through LoopXPay's First Live B2B Agentic Transaction
2026-07-24 12:00
15781
Phuket Marriott Resort & Spa, Merlin Beach Elevates Guest Experience with New Dining and Family Facilities
2026-07-24 18:32
14248
Courtyard by Marriott Phuket, Patong Beach Wins TripAdvisor Best of the Best Award
2026-07-24 16:25
13239
